State Street SPDR S&P Biotech ETF vs Block Inc — how do they compare? State Street SPDR S&P Biotech ETF trades at $154.5, while Block Inc trades at $80.35 (market cap $47.19B). Which is the better fit depends on your goals.
| XBI | XYZ | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $164.28 | $81.81 |
52-Week Low | $85.16 | $49.04 |
Market Cap | — | $47.19B |
Enterprise Value | — | $42.06B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XYZ trades at $80.38, up 0.55% today, with a bullish technical signal and strong analyst consensus. Recent Q1 2026 earnings beat expectations, but net income margin fell to 3.3% in 2025. The stock is supported by positive sentiment from Zacks upgrades and momentum coverage, though it faces risks from a recent $45 million settlement and mixed cash flow trends.
The outlook is cautiously optimistic, with a consensus price target of $89.64 offering ~12% upside. Key opportunities include earnings growth and Cash App strength, but risks involve credit losses, regulatory scrutiny, and a high P/E ratio of 61.95. Institutional selling and insider sales add near-term pressure.
Trailing returns across standard periods
Latest headlines on both assets
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →